Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Simufilam (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Registrational; Therapeutic Use
  • Acronyms RETHINK-1; RETHINK-ALZ
  • Sponsors Cassava Sciences

    • Most Recent Events

    • 08 Oct 2024 Planned End Date changed from 1 Oct 2024 to 15 Oct 2024.
    • 08 Oct 2024 Planned primary completion date changed from 1 Oct 2024 to 15 Oct 2024.
    • 25 Sep 2024 According to a Cassava Sciences media release, the company announced the completion of a third interim patient safety review by an Independent Data and Safety Monitoring Board (DSMB). DSMB recommended that trial continue as planned, without modification. Topline data from this trial expected before year end 2024. Final safety data are expected at the conclusion of the Phase 3 program.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top